Advocacy intelligence hub — real-time data for patient organizations
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs3
CABOMETYX
(cabozantinib)Orphan drugstandardExelixis, Inc.
12.1 Mechanism of Action In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of MET, VEGFR-...
CYRAMZA
(ramucirumab)Orphan drugstandardEli Lilly and Company
Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]
12.1 Mechanism of Action Ramucirumab is a VEGFR2 antagonist that specifically binds VEGFR2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VE...
Wei Wei, Ph.D, M,D
Sun Yat-sen University
Jianbo Chen
The First Affiliated Hospital of Xiamen University
Yongzhong Wang
Sanming Second Hospital
Wei-Ting Chen, MD, LPC
Chang Gung Memorial Hospital
📍 HOUSTON, TX
Feng Ye, M.D
The First Affiliated Hospital of Xiamen University
📍 BURLINGTON, MA
congren Wang
Quanzhou First Hospital